Fabrication and characterization of an inorganic gold and silica nanoparticle mediated drug delivery system for nitric oxide.

Publication Type:

Journal Article

Source:

Nanotechnology, Volume 21, Issue 30, p.305102 (2010)

Keywords:

Cell Proliferationdigestive disease, digestive deseases Drug Delivery Systemsdigestive disease, digestive deseases Endocytosisdigestive disease, digestive deseases Golddigestive disease, digestive deseases Hepatic Stellate Cellsdigestive disease, digestive deseases Humansdigestive disease, digestive deseases Kineticsdigestive disease, digestive deseases Metal Nanoparticlesdigestive disease, digestive deseases Nanomedicinedigestive disease, digestive deseases Neovascularization, Physiologicdigestive disease, digestive deseases Nitric Oxidedigestive disease, digestive deseases Nitric Oxide Donorsdigestive disease, digestive deseases Phenotypedigestive disease, digestive deseases S-Nitroso-N-Acetylpenicillaminedigestive disease, digestive deseases Silicon Dioxidedigestive disease, digestive deseases Spectrophotometry, Ultraviolet

Abstract:

Nitric oxide (NO) plays an important role in inhibiting the development of hepatic fibrosis and its ensuing complication of portal hypertension by inhibiting human hepatic stellate cell (HSC) activation. Here we have developed a gold nanoparticle and silica nanoparticle mediated drug delivery system containing NO donors, which could be used for potential therapeutic application in chronic liver disease. The gold nanoconjugates were characterized using several physico-chemical techniques such as UV-visible spectroscopy and transmission electron microscopy. Silica nanoconjugates were synthesized and characterized as reported previously. NO released from gold and silica nanoconjugates was quantified under physiological conditions (pH = 7.4 at 37 degrees C) for a substantial period of time. HSC proliferation and the vascular tube formation ability, manifestations of their activation, were significantly attenuated by the NO released from these nanoconjugates. This study indicates that gold and silica nanoparticle mediated drug delivery systems for introducing NO could be used as a strategy for the treatment of hepatic fibrosis or chronic liver diseases, by limiting HSC activation.